All articles by GlobalData 

  1. Increased diagnosis and comprehensive treatment of mood disorders in cases of BED is crucial to recovery

    Binge eating disorder (BED) is characterised by eating large quantities of food all at once during a set time period….
    Read More…

    10 Apr
  2. Dupixent likely to maintain its position in the market for atopic dermatitis

    Regeneron Pharmaceuticals’ Dupixent (dupilumab) is likely to maintain its foothold in moderate-to-severe atopic dermatitis (AD) in the foreseeable future considering…
    Read More…

    9 Apr
  3. PARP inhibitors make inroads in pancreatic cancer

    Preliminary data from a Phase II trial of Clovis Oncology’s Rubraca (rucaparib) for maintenance of advanced BRCA- or PALB2-related pancreatic…
    Read More…

    9 Apr
  4. Innovation in asthma pipeline is focused on targeted biologic therapies

    The asthma market is saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs) and inhaled corticosteroids (ICSs), but…
    Read More…

    9 Apr
  5. AstraZeneca bolsters oncology portfolio with Daiichi Sankyo’s trastuzumab deruxtecan

    AstraZeneca has pursued a deal to bolster its position in the oncology market through shared development and commercialisation of Daiichi…
    Read More…

    9 Apr
  6. Comorbid conditions that complicate Atopic dermatitis

    Atopic dermatitis (AD), a condition causing red and itchy skin, affects more than 40 million people in the US annually….
    Read More…

    9 Apr
  7. Epigenetics: an exciting new approach in prostate cancer

    In a company first, Zenith Epigenetics is presenting preliminary Phase II results from its investigation of the epigenetic protein inhibitor,…
    Read More…

    9 Apr
  8. Reducing misconceptions around cervical cancer screening in the UK

    Many women in the UK have a negative opinion about cervical smear testing. As such, cervical screening rates have hit…
    Read More…

    8 Apr
Close
Close
Close

Go Top